ECSP17084137A - Neoantígenos compartidos - Google Patents

Neoantígenos compartidos

Info

Publication number
ECSP17084137A
ECSP17084137A ECIEPI201784137A ECPI201784137A ECSP17084137A EC SP17084137 A ECSP17084137 A EC SP17084137A EC IEPI201784137 A ECIEPI201784137 A EC IEPI201784137A EC PI201784137 A ECPI201784137 A EC PI201784137A EC SP17084137 A ECSP17084137 A EC SP17084137A
Authority
EC
Ecuador
Prior art keywords
tumor
subjects
specific
population
neoantigenic
Prior art date
Application number
ECIEPI201784137A
Other languages
English (en)
Spanish (es)
Inventor
Michael Rooney
Edward Fritsch
Jing Sun
Catherine J Wu
Sachet Shukla
Nir Hacohen
Pavan Bachireddy
Original Assignee
Massachusetts Gen Hospital
Broad Inst Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital, Broad Inst Inc, Dana Farber Cancer Inst Inc filed Critical Massachusetts Gen Hospital
Publication of ECSP17084137A publication Critical patent/ECSP17084137A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
    • A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ECIEPI201784137A 2015-05-20 2017-12-20 Neoantígenos compartidos ECSP17084137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562179877P 2015-05-20 2015-05-20
US201662389377P 2016-02-23 2016-02-23

Publications (1)

Publication Number Publication Date
ECSP17084137A true ECSP17084137A (es) 2018-05-31

Family

ID=56203902

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201784137A ECSP17084137A (es) 2015-05-20 2017-12-20 Neoantígenos compartidos

Country Status (21)

Country Link
US (2) US10835585B2 (enExample)
EP (1) EP3297660A2 (enExample)
JP (3) JP6913032B2 (enExample)
KR (2) KR20180010229A (enExample)
CN (2) CN116196401B (enExample)
AU (3) AU2016264623B2 (enExample)
BR (1) BR112017024797A2 (enExample)
CA (1) CA2986235A1 (enExample)
CL (2) CL2017002945A1 (enExample)
CO (1) CO2017012835A2 (enExample)
CR (3) CR20200476A (enExample)
EC (1) ECSP17084137A (enExample)
HK (1) HK1252267A1 (enExample)
IL (3) IL255769B2 (enExample)
MX (3) MX2017014700A (enExample)
MY (1) MY190974A (enExample)
PE (1) PE20180670A1 (enExample)
PH (1) PH12017502321A1 (enExample)
RU (1) RU2733754C2 (enExample)
TW (3) TWI878795B (enExample)
WO (1) WO2016187508A2 (enExample)

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
WO2017124147A1 (en) * 2016-01-19 2017-07-27 The University Of Western Australia Novel biomolecule conjugates and uses therefor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
WO2017190218A1 (en) * 2016-05-06 2017-11-09 University Health Network Liquid-biopsy signatures for prostate cancer
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN109923121B (zh) * 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
KR102993694B1 (ko) 2016-12-09 2026-07-22 더 브로드 인스티튜트, 인코퍼레이티드 Crispr 이펙터 시스템 기반 진단
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CN106868133A (zh) * 2017-02-24 2017-06-20 北京致成生物医学科技有限公司 一种监测肿瘤发生发展的产品及其应用
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
CN111108220B (zh) 2017-03-15 2024-11-19 博德研究所 用于病毒检测的基于crispr效应系统的诊断
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN108659114B (zh) * 2017-04-01 2022-10-21 中国科学院广州生物医药与健康研究院 识别pasd1抗原短肽的tcr
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
CA3061240C (en) * 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
WO2018209015A1 (en) * 2017-05-10 2018-11-15 University Of Connecticut Dendritic cells as a novel delivery system for immunotherapy
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
AU2018287169B2 (en) * 2017-06-22 2024-11-14 Neogap Therapeutics Ab T-cell expansion method and uses
NL2019156B1 (en) * 2017-06-30 2019-01-10 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Treatment of haematological malignancies
CN111032686B (zh) * 2017-06-30 2024-05-14 莱顿大学医学中心附属莱顿教学医院 血液恶性肿瘤的治疗
US20220305102A1 (en) * 2017-06-30 2022-09-29 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
CN107325171A (zh) * 2017-07-06 2017-11-07 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用
CN107188955A (zh) * 2017-07-06 2017-09-22 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用
KR20200026898A (ko) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
BR112020000590A2 (pt) 2017-07-12 2020-07-14 Nouscom Ag método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019031938A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
KR102946326B1 (ko) * 2017-09-05 2026-03-31 시애틀 프로젝트 코포레이션 T-세포 요법을 위한 신생항원 동정
US11203615B2 (en) 2017-09-11 2021-12-21 National University Corporation Hokkaido University Cancer treatment drug
IL273515B2 (en) 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
KR102857066B1 (ko) 2018-01-29 2025-09-08 더 브로드 인스티튜트, 인코퍼레이티드 Crispr 이펙터 시스템 기반 진단
SG11202007750PA (en) * 2018-02-15 2020-09-29 National Univ Corporation Asahikawa Medical Univ Cancer antigen peptide
US20210238690A1 (en) * 2018-04-26 2021-08-05 Intellexon Gmbh Hla-j and medical/diagnostic uses thereof
AU2019263233B2 (en) * 2018-05-01 2024-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors which recognize mutated EGFR
WO2019217837A1 (en) * 2018-05-11 2019-11-14 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CN108588201B (zh) * 2018-05-11 2019-08-09 浙江省人民医院 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置
CN112899350B (zh) * 2018-05-14 2023-01-24 北京艾克伦医疗科技有限公司 核酸检测方法和试剂盒
TW202000907A (zh) 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 共有抗原
US12528848B2 (en) 2018-05-25 2026-01-20 The Wistar Institute Of Anatomy And Biology Tumor-specific neoantigens and methods of using the same
CN108728529B (zh) * 2018-06-06 2020-08-04 青岛泱深生物医药有限公司 Znf770基因在制备诊治子痫前期的产品中的应用
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN109142729B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-hmgb3自身抗体及其应用
CA3103181A1 (en) * 2018-06-18 2019-12-26 College De France Ligand controling interaction between gags with their effector molecules and use thereof
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
GB201810358D0 (en) * 2018-06-25 2018-08-08 Univ College Cardiff Consultants Ltd Cancer-specific t-cell receptors
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
US12268690B2 (en) 2018-07-27 2025-04-08 Oregon Health & Science University Treatments for mutations in acute myeloid leukemia
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
CN113039612A (zh) * 2018-08-28 2021-06-25 赛科维有限两合公司 分级和/或选择肿瘤特异性新抗原的方法
US20220160870A1 (en) * 2018-08-28 2022-05-26 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
CN109022585A (zh) * 2018-09-10 2018-12-18 路君 Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用
WO2020059772A1 (ja) * 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109207431B (zh) * 2018-10-12 2021-10-15 武汉大学 一种抑制人癌基因STAT3的α亚型表达的方法
CN109486935A (zh) * 2018-10-18 2019-03-19 中国医学科学院北京协和医院 作为骨质疏松症诊治靶标的aknad1基因
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
CN111116754A (zh) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性tcr及其应用
WO2020092705A1 (en) * 2018-10-31 2020-05-07 University Of Virginia Patent Foundation Self-assembling peptides and hydrogels
JPWO2020090979A1 (ja) * 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
TW202031677A (zh) 2018-11-01 2020-09-01 美商博得學院股份有限公司 Ｐｄｅ３調節劑反應性癌症之鑑定
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
CN109504771A (zh) * 2018-11-19 2019-03-22 北京大学深圳医院（北京大学深圳临床医学院） Adcy2作为乳腺癌的分子标记物的应用
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
CN109371026A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
CN111363816B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于pax3和zic4基因的肺癌诊断试剂及试剂盒
CN109576362B (zh) * 2018-12-28 2020-09-04 青岛泱深生物医药有限公司 阿尔茨海默诊治用标志物fam170a
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
US20220125839A1 (en) * 2019-02-13 2022-04-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene
JP2022521738A (ja) 2019-02-20 2022-04-12 ルビウス セラピューティクス， インコーポレイテッド 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
CN109735624A (zh) * 2019-03-14 2019-05-10 台州市立医院 基因标志物在甲状腺癌诊断中的应用
EP3941932A1 (en) * 2019-03-21 2022-01-26 Institute for Research in Biomedicine Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
EP3972632A1 (en) * 2019-05-20 2022-03-30 BioNTech SE Therapeutic rna for ovarian cancer
JP7585237B2 (ja) * 2019-05-23 2024-11-18 クリスティアナ ケア ジーン エディティング インスティテュート，インコーポレーテッド がんを処置するためのバリアントｎｒｆ２の遺伝子ノックアウト
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
US11306122B2 (en) * 2019-06-14 2022-04-19 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
CN114245745A (zh) * 2019-06-20 2022-03-25 纪念斯隆-凯特琳癌症中心 靶向pik3ca突变的t细胞受体及其用途
CN110358827A (zh) * 2019-07-09 2019-10-22 中国人民解放军第四军医大学 Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备
CN110358831B (zh) * 2019-07-11 2021-12-24 江苏医药职业学院 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒
WO2021011417A1 (en) * 2019-07-12 2021-01-21 The Regents Of The University Of California Chemically controlled monoclonal antibody target engagement
WO2021011798A1 (en) * 2019-07-16 2021-01-21 Washington University Anti-grp78 antibodies and method of use thereof
US20220265792A1 (en) * 2019-07-30 2022-08-25 Breakbio Corp. Methods for treating solid tumors
WO2021030358A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
AU2020334237B2 (en) * 2019-08-19 2025-11-13 Universität Basel Cell therapy methods
CN112402612B (zh) * 2019-08-21 2023-05-26 苏州蓝马医疗技术有限公司 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法
KR20220070487A (ko) * 2019-09-26 2022-05-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역원성 egfr 펩타이드 조성물 및 암의 치료에서 그의 용도
WO2021092331A1 (en) * 2019-11-06 2021-05-14 Ohio State Innovation Foundation Targeting circular pcmtd1 in leukemias with p53 mutations and/or bcr/abl fusions
US12570696B2 (en) * 2019-11-07 2026-03-10 Shenzhen Gino Biotechnology Co., Ltd. Tumor-specific polypeptide sequence and use thereof
CA3157411A1 (en) * 2019-11-15 2021-05-20 Karin Jooss Antigen-binding proteins targeting shared neoantigens
CN114729403A (zh) * 2019-11-22 2022-07-08 新加坡国立大学 用于鉴定和验证共有候选抗原和共有抗原特异性t淋巴细胞对的方法和系统
WO2021127184A1 (en) 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
JP2023507854A (ja) 2019-12-23 2023-02-27 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｍｈｃ複合体の安定化
CN113117081B (zh) * 2019-12-30 2024-12-24 上海海洋大学 ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法
KR102764120B1 (ko) * 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
CN111116728B (zh) * 2020-01-13 2021-04-27 郑州大学 肿瘤特异性抗原ctl表位肽及其应用
AU2021209740A1 (en) * 2020-01-21 2022-07-14 Shanghai Biotroy Biotechnique Co., Ltd. SEMG2 antibody and use thereof
EP4107176A4 (en) * 2020-02-20 2024-03-20 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING THE SHARED ANTIGEN KKLC-1
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
AU2021238582A1 (en) * 2020-03-16 2022-09-22 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
CN113461798A (zh) * 2020-03-18 2021-10-01 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
EP4149952A1 (en) * 2020-05-12 2023-03-22 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
CN113817740B (zh) * 2020-06-19 2024-07-09 中国科学院化学研究所 一种核酸适配体识别并结合ptprf及其相关功能的应用研究
CN111718405B (zh) * 2020-06-30 2022-09-13 青岛海兰深生物科技有限公司 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法
WO2022000399A1 (en) * 2020-07-02 2022-01-06 The Johns Hopkins University Methylated markers for accurate detection of primary central nervous system and systemic diffuse large b cell lymphoma
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
US12440537B1 (en) * 2020-10-13 2025-10-14 Washington University Compositions and methods for treating skin diseases, disorders, or conditions
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
JP7829242B2 (ja) * 2020-11-20 2026-03-13 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
WO2022140759A2 (en) * 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
CN112666358A (zh) * 2021-01-14 2021-04-16 深圳裕康医学检验实验室 一种使用外周血检测抗原免疫原性的方法
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
WO2022179568A1 (en) * 2021-02-25 2022-09-01 Westlake Therapeutics (Hangzhou) Co., Limited Neoantigenic peptide and its use for treating braf gene mutation related diseases
CN117062832A (zh) * 2021-03-16 2023-11-14 上海柏全生物科技有限公司 精液凝固蛋白的中和抗体及其表位和应用
CN113667002B (zh) * 2021-03-24 2023-03-28 深圳市新靶向生物科技有限公司 一种与肺癌驱动基因突变相关的抗原肽及其应用
CN114230656B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用
CN114163510B (zh) * 2021-03-24 2024-12-06 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
JP2024516542A (ja) * 2021-04-06 2024-04-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍｈｃクラスｉペプチドを含む方法および組成物
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
IL282814A (en) * 2021-04-29 2022-11-01 Yeda Res & Dev T cell receptors directed against ras-derived recurrent neoantigens
BR112023022485A2 (pt) 2021-04-30 2024-01-09 Centre Hospitalier Univ Vaudois Chuv Expansão de linfócitos em um único recipiente
CN113527464B (zh) * 2021-07-19 2024-10-18 新景智源生物科技(苏州)有限公司 识别mboat2的tcr
KR20240109977A (ko) 2021-08-26 2024-07-12 볼라스트라 쎄라퓨틱스, 인코포레이티드 Kif18a의 스피로 인돌린 억제제
CN117741161B (zh) * 2021-08-30 2026-07-07 河南中医药大学 Plekho2和npm3自身抗体在制备检测桥本甲状腺炎阴虚火旺证试剂盒中的应用
CN114085281A (zh) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 一种肿瘤抗原表位肽及其多聚体和应用
CN114085282A (zh) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用
EP4423256A2 (en) * 2021-10-28 2024-09-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention
US20250025499A1 (en) * 2021-11-02 2025-01-23 Fred Hutchinson Cancer Center T cell immunotherapy for hematologic malignancies having an sf3b1 mutation
KR102753583B1 (ko) 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
CN114177274A (zh) * 2021-12-13 2022-03-15 中国医学科学院微循环研究所 Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物
US20250034252A1 (en) * 2021-12-16 2025-01-30 The Johns Hopkins University Manabodies targeting p53 tumor antigens and methods of using
KR102732909B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
EP4476268A4 (en) * 2022-02-07 2026-04-15 Ubiquitx BETA-CATENIN PROTEIN DEGRADATION
CN114524872A (zh) * 2022-03-09 2022-05-24 广州诺诚生物技术研发有限公司 一种用于乳腺癌检测的单克隆抗体及其试剂盒
KR102772405B1 (ko) * 2022-06-10 2025-02-26 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도
WO2023243698A1 (en) * 2022-06-15 2023-12-21 Okinawa Institute Of Science And Technology School Corporation Peptides for opioid tolerance by blocking receptors dimerization
CN115327125A (zh) * 2022-07-14 2022-11-11 宁波大学 一种蛋白质inf2在制备肝癌诊断标志物中的应用
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
CN115651984B (zh) * 2022-10-20 2023-04-14 山东大学 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用
AU2023372974A1 (en) 2022-11-02 2025-06-12 Centre Hospitalier Universitaire Vaudois (Chuv) Expansion of lymphocytes
EP4368189A1 (en) * 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms
CN116024217A (zh) * 2023-01-16 2023-04-28 陕西师范大学 Mff作为靶点在制备治疗卵巢癌和/或评估患卵巢癌风险产品中的应用
CN116694760A (zh) * 2023-03-21 2023-09-05 山东大学齐鲁医院 生物标记物ccdc60在癌症中的应用
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
CN116948004B (zh) * 2023-09-13 2023-11-21 成都朗谷生物科技股份有限公司 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用
WO2025064339A1 (en) * 2023-09-18 2025-03-27 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
CN117567591B (zh) * 2024-01-11 2024-04-26 中国人民解放军总医院 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用
TW202539700A (zh) * 2024-01-16 2025-10-16 美商建南德克公司 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法
LU103243B1 (en) 2024-02-09 2025-08-11 PMCR GmbH Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same
WO2025168848A1 (en) 2024-02-09 2025-08-14 IMMUNEO Therapeutics GmbH Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
CN118085058B (zh) * 2024-02-29 2024-08-30 漯河医学高等专科学校 Obscn新抗原表位肽及其应用
CN118326008A (zh) * 2024-04-18 2024-07-12 香港大学深圳医院 一种基于panel基因测序数据的肿瘤新抗原、筛选方法及应用
CN118955677B (zh) * 2024-05-29 2025-07-22 北京艺升控股有限公司 一种抗原肽及其应用
CN118930636A (zh) * 2024-07-17 2024-11-12 中国科学院微生物研究所 一种急性髓系白血病表位肽dnmt3a-r882s的t细胞受体及其应用
CN119320833B (zh) * 2024-12-18 2025-07-11 南京农业大学 一种与鸡双黄蛋性状相关的ston1基因分子标记引物及其应用
CN120384053A (zh) * 2025-04-29 2025-07-29 西湖大学 工程化的nk细胞及其制备方法和应用
CN121021702A (zh) * 2025-08-26 2025-11-28 苏州系统医学研究所 Glyr1靶向抗体、其制备方法及在肿瘤防治中的应用
CN121059808B (zh) * 2025-11-05 2026-01-30 哈尔滨医科大学 Pwwp2b作为靶点在制备白血病治疗药物中的应用

Family Cites Families (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4226859A (en) 1979-06-07 1980-10-07 Velsicol Chemical Corporation Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816540A (en) 1987-06-12 1989-03-28 Yasuhiko Onishi Cationic graft-copolymer
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
WO1992014486A1 (en) 1991-02-22 1992-09-03 THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE Transmission blocking vaccine against malaria
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
ES2243937T3 (es) 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
CN1367830A (zh) 1998-10-05 2002-09-04 路德维哥癌症研究院 癌症相关抗原及其应用
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP1189624A4 (en) 1999-06-29 2005-02-23 Epimmune Inc Hla binding peptides and their uses
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2003523365A (ja) 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
KR100880765B1 (ko) 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
US6686184B1 (en) 2000-05-25 2004-02-03 President And Fellows Of Harvard College Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US6923973B1 (en) 2001-02-22 2005-08-02 Board Of Regents, The University Of Texas System Peptide and DNA immunization against Coccidioides immitis infections
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CA2488382A1 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
ATE519115T1 (de) 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
JP2006507921A (ja) 2002-06-28 2006-03-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 流体分散のための方法および装置
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
CA2511625A1 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CA2521862C (en) 2003-04-10 2012-10-16 President And Fellows Of Harvard College Formation and control of fluidic species
SI1620456T1 (sl) 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
CN1842368B (zh) 2003-08-27 2014-05-28 哈佛大学 流体物种的电子控制
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US7084247B2 (en) 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
EP2573185A3 (en) 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use
US9039273B2 (en) 2005-03-04 2015-05-26 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
JP4976294B2 (ja) 2005-08-03 2012-07-18 株式会社医学生物学研究所 細胞傷害性ｔ細胞エピトープペプチド及びその用途
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
WO2007081385A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
WO2007089541A2 (en) 2006-01-27 2007-08-09 President And Fellows Of Harvard College Fluidic droplet coalescence
US8793895B2 (en) 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
JP2009532664A (ja) 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2007133710A2 (en) 2006-05-11 2007-11-22 Raindance Technologies, Inc. Microfluidic devices and methods of use thereof
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
ES2539042T3 (es) 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
WO2008011344A2 (en) 2006-07-17 2008-01-24 Nationwide Children's Hospital Inc. Disruption of programmed death-1 (pd-1) ligands to adjuvant adeno-associated virus vector vaccines
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
US8349167B2 (en) 2006-12-14 2013-01-08 Life Technologies Corporation Methods and apparatus for detecting molecular interactions using FET arrays
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
CN105664147A (zh) 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
US20100099090A1 (en) 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2829282B1 (en) 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JP5548616B2 (ja) 2007-08-08 2014-07-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆｒ−１／ｎｒｐ−１標的化ペプチド
CA2699078A1 (en) 2007-09-11 2009-04-09 Dorian Bevec Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
TR201802233T4 (tr) 2007-10-25 2018-03-21 Toray Industries İmmün cevap indükleyiciler.
AU2008345036A1 (en) 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer
JP2011512326A (ja) 2007-12-31 2011-04-21 ナノコア セラピューティクス，インコーポレイテッド 心不全の治療用のｒｎａ干渉
WO2009102909A2 (en) 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Anti-cancer vaccines
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
AU2009303392A1 (en) 2008-10-17 2010-04-22 Genentech, Inc. Treatment method
US20100137143A1 (en) 2008-10-22 2010-06-03 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010112962A1 (en) 2009-04-02 2010-10-07 Vaxon Biotech Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
EP2509583B1 (en) 2009-12-10 2019-05-15 Merck Patent GmbH Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CN102946907A (zh) 2010-05-28 2013-02-27 牛津生物医学（英国）有限公司 慢病毒载体向脑的递送
CN103221042B (zh) 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012095639A2 (en) 2011-01-14 2012-07-19 Genefirst Limited Methods, compositions, and kits for determing the presence/absence of a varian nucleic acid sequence
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
EP2744912B1 (en) 2011-08-18 2016-11-02 Nestec S.A. Compositions and methods for detecting allelic variants
EP2753345B1 (en) 2011-09-06 2016-07-13 Agency For Science, Technology And Research Polypeptide vaccine
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013086464A1 (en) 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130210014A1 (en) 2012-02-10 2013-08-15 Jeff Sharman Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients
AU2013221642A1 (en) 2012-02-15 2014-09-25 Janssen Diagnostics, Llc Highly sensitive method for detecting low frequency mutations
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
AU2013273987B2 (en) 2012-06-15 2018-08-09 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
JP6923291B2 (ja) 2012-07-12 2021-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
IN2014DN10889A (enExample) 2012-07-13 2015-09-11 Univ Pennsylvania
NZ741124A (en) 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
WO2014036562A2 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
WO2014047561A1 (en) 2012-09-21 2014-03-27 The Broad Institute Inc. Compositions and methods for labeling of agents
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014056986A1 (en) 2012-10-11 2014-04-17 Universitat De Barcelona Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll)
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
WO2014085802A1 (en) 2012-11-30 2014-06-05 The Broad Institute, Inc. High-throughput dynamic reagent delivery system
JP6544861B2 (ja) 2013-02-07 2019-07-17 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 高い選択性の核酸増幅プライマー
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
JP6257655B2 (ja) 2013-03-01 2018-01-10 アメリカ合衆国 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
WO2014133567A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US10176294B2 (en) 2013-03-15 2019-01-08 The Broad Institute, Inc. Accurate typing of HLA through exome sequencing
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014172606A1 (en) 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
AU2014275166B2 (en) * 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
JP6740127B2 (ja) 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
US10690658B2 (en) 2014-06-05 2020-06-23 Aimm Therapeutics B.V. Means and methods for determining T cell recognition
SI3198026T1 (sl) 2014-08-07 2020-02-28 Pharmassist Ltd Metoda za analiziranje DNA PIK3CA mutantnega statusa v vzorcu
WO2016048952A1 (en) 2014-09-22 2016-03-31 The Broad Institute Inc. Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US20190099475A1 (en) * 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CA3172682A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2016183042A1 (en) 2015-05-10 2016-11-17 Quandx Inc. Ultra sensitive probes for detection of nucleic acid
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide

Also Published As

Publication number Publication date
PH12017502321A1 (en) 2018-06-25
IL255769A (en) 2018-01-31
JP7282834B2 (ja) 2023-05-29
US20180153975A1 (en) 2018-06-07
US20200368337A1 (en) 2020-11-26
IL302102B1 (en) 2026-03-01
IL294183B2 (en) 2023-10-01
TW202346325A (zh) 2023-12-01
IL302102B2 (en) 2026-07-01
CN108025048B (zh) 2022-10-25
RU2017144467A3 (enExample) 2019-11-20
CA2986235A1 (en) 2016-11-24
TWI806815B (zh) 2023-07-01
AU2025204711A1 (en) 2025-07-10
CR20230191A (es) 2023-07-06
WO2016187508A2 (en) 2016-11-24
TWI878795B (zh) 2025-04-01
AU2022241521A1 (en) 2022-12-01
RU2017144467A (ru) 2019-06-20
HK1252267A1 (zh) 2019-05-24
MX2023005122A (es) 2023-07-13
IL302102A (en) 2023-06-01
AU2016264623A1 (en) 2017-12-07
TW201808327A (zh) 2018-03-16
CN108025048A (zh) 2018-05-11
CL2017002945A1 (es) 2018-04-27
MY190974A (en) 2022-05-25
MX2024006806A (es) 2024-06-21
CL2023002421A1 (es) 2024-02-09
TW202523682A (zh) 2025-06-16
RU2020132040A (ru) 2020-10-12
JP6913032B2 (ja) 2021-08-04
JP2018522822A (ja) 2018-08-16
JP2021176866A (ja) 2021-11-11
CO2017012835A2 (es) 2018-05-10
NZ737891A (en) 2025-02-28
JP7856604B2 (ja) 2026-05-11
IL255769B1 (en) 2023-05-01
CR20200476A (es) 2020-12-02
MX2017014700A (es) 2018-08-15
NZ776159A (en) 2025-03-28
JP2023103405A (ja) 2023-07-26
AU2016264623B2 (en) 2022-06-30
WO2016187508A3 (en) 2017-01-12
US10835585B2 (en) 2020-11-17
CR20170584A (es) 2018-03-20
EP3297660A2 (en) 2018-03-28
BR112017024797A2 (pt) 2018-08-07
PE20180670A1 (es) 2018-04-19
KR20240166604A (ko) 2024-11-26
RU2733754C2 (ru) 2020-10-06
KR20180010229A (ko) 2018-01-30
HK1251148A1 (zh) 2019-01-25
IL294183A (en) 2022-08-01
AU2022241521B2 (en) 2025-09-11
CN116196401A (zh) 2023-06-02
CN116196401B (zh) 2026-05-15
IL294183B1 (en) 2023-06-01
IL255769B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CL2023002421A1 (es) Neoantígenos compartidos
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CY1124224T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
CY1123902T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι tου καρκινου του οισοφαγου και αλλων καρκινων
CO2019010524A2 (es) Plataforma de identificación de péptidos inmunogénicos basada en población
CR20200409A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
MX2018009228A (es) Proteínas de unión a antigeno que se unen a pd-l1.
MX2017004669A (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer.
PE20200781A1 (es) Proteinas de union a antigenos de maduracion de celulas b (bcma), de un solo dominio
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
UY37456A (es) Inmunoglobulinas y sus usos
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
CY1124813T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων μορφων καρκινου
UY36344A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer